---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-005339"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:12:36.638432+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab (BGLC) announces MyCIF co-investment in AISB, total round RM 1.7M (~$390k)

## Summary
- Malaysian Securities Commission co-invests alongside BGLC in Ascension Innovation under ESI scheme; total round RM 1.7M (~USD 390k).
- BGLC previously invested RM 1M; AISB is first recipient of MyCIF ESI scheme.
- Proceeds to advance AI-driven healthcare platform aiCMS and support Malaysia's National EMR Plan 'One Patient, One Record'.
- CEO Sam Tan cites confidence from government investment in AISB's technology and BGLC's strategic direction.

## SEC filing metadata
- accession: 0001477932-24-005339
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224005339/0001477932-24-005339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224005339/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-005339
- JSON: https://secwatch.observer/filing/0001477932-24-005339.json
- Plain text: https://secwatch.observer/filing/0001477932-24-005339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.